Literature DB >> 17314997

Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study.

V Barrios1, C Escobar, A Calderón, R Echarri, V González-Pedel, L M Ruilope.   

Abstract

The CONTROLRISK study was designed to determine the cardiovascular risk profile of the hypertensive population attended at primary care and specialist setting in Spain and to investigate whether physicians stratify the risk correctly, according to the 2003 European guidelines. A total of 8920 patients were recruited from primary care (n=4485) and specialist outpatient clinic (n=4435). The age criteria was 62.6+/-11.1 years; 51.6% were women. No differences were observed in the severity of hypertension. More than 85% presented other cardiovascular risk factors, similarly in both groups. Target organ damage (TOD) and associated clinical conditions (ACC) were more frequent in specialist setting (57.6 vs 34.3% and 39 vs 28.7%, both P<0.0001). The most common risk factor was age. The most frequently reported TOD was left ventricular hypertrophy (42.3 and 22.1%; P<0.0001). Ischemic heart disease was the most common ACC (21.5 vs 13.1%; P<0.0001). The risk profile was significantly higher in specialist population (75.1 vs 60.3% of patients belonged to high- or very high-risk groups). Specialists and primary care physicians stratified only 54.6 and 48% of their patients correctly, respectively (P<0.05). Both, specialists and general practitioners (GPs) strongly underestimated the risk. Very high-risk patients were adequately assessed only in 44.9% of cases by specialists and in 25.3% by GPs (P<0.001). More than half of the hypertensive patients attended by GPs in Spain belong to the high- or very high-risk groups. GPs and specialists tend to underestimate the cardiovascular risk in daily clinical practice, mainly in very high-risk patients.

Entities:  

Mesh:

Year:  2007        PMID: 17314997     DOI: 10.1038/sj.jhh.1002167

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  13 in total

Review 1.  Risk Alteration for Atrial Fibrillation with DifferentAntihypertensive Drugs.

Authors:  Vivencio Barrios; Carlos Escobar
Journal:  J Atr Fibrillation       Date:  2011-12-20

2.  Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study.

Authors:  Vivencio Barrios; Peter Brommer; Uwe Haag; Alberto Calderón; Carlos Escobar
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 3.  Cardiovascular high-risk patients--treat to protect, but whom?

Authors:  Faiez Zannad; Anne Jakobsen; Jose Heroys; Ann Ralph; Tomas Rees; Michael Shaw
Journal:  Medscape J Med       Date:  2008-03-26

Review 4.  Cardiovascular protection for all individuals at high risk: evidence-based best practice.

Authors:  George Bakris; Michael Böhm; Gilles Dagenais; Hans-Christoph Diener; Toshiro Fujita; Philip Gorelick; Sverre Erik Kjeldsen; Markku Laakso; Giuseppe Mancia; Bertram Pitt; Arya Sharma; Peter Sleight; Koon Teo; Thomas Unger; Michael Weber; Bryan Williams; Faiez Zannad
Journal:  Clin Res Cardiol       Date:  2008-08-23       Impact factor: 5.460

5.  Effectiveness of an Interventional Program to Improve Blood Pressure Control in Hypertensive Patients at High Risk for Developing Heart Failure: HEROIC study.

Authors:  Beatriz De Rivas; Vivencio Barrios; Josep Redón; Alberto Calderón
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-05       Impact factor: 3.738

6.  Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension - update on clinical utility.

Authors:  Vivencio Barrios; Carlos Escobar
Journal:  Integr Blood Press Control       Date:  2010-05-10

7.  Sex differences in the hypertensive population with chronic ischemic heart disease.

Authors:  Vivencio Barrios; Carlos Escobar; Vicente Bertomeu; Nekane Murga; Carmen de Pablo; Alberto Calderón
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-10       Impact factor: 3.738

8.  Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study.

Authors:  Carlos Escobar; Vivencio Barrios; Alberto Calderón; Sara Barrios; Rocio Echarri; Josefa Navarro-Cid; Elena Ferrer; Raúl Fernandez
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-03       Impact factor: 3.738

Review 9.  Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril.

Authors:  Vivencio Barrios; Carlos Escobar; Rocio Echarri
Journal:  Vasc Health Risk Manag       Date:  2008

Review 10.  Relative safety profiles of high dose statin regimens.

Authors:  Carlos Escobar; Rocio Echarri; Vivencio Barrios
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.